Record Nr. UNINA9910483977303321 Immunotherapy - a novel facet of modern therapeutics / / edited by **Titolo** Sujata P. Sawarkar, Vandana S. Nikam, Shariq Syed Pubbl/distr/stampa Singapore:,: Springer,, [2021] ©2021 981-15-9038-9 **ISBN** Edizione [1st ed. 2021.] 1 online resource (VIII, 262 p. 15 illus., 12 illus. in color.) Descrizione fisica 354.81150006 Disciplina Cancer - Research Soggetti Human physiology **Immunotherapy** Lingua di pubblicazione Inglese **Formato** Materiale a stampa Livello bibliografico Monografia Nota di contenuto Chapter 1. Immunotherapy – a Concept -- Chapter 2. Immunotherapy in Cancer - Immune Checkpoint Inhibitors; changing Oncology treatment paradigm -- Chapter 3. Vaccines as Immunotherapy --Chapter 4. Immunotherapy for Autoimmune Diseases -- Chapter 5. Immunotherapy in neurodegenerative disorders -- Chapter 6. Companion diagnostics and clinical biomarkers for immunotherapy --Chapter 7. Novel Drug Delivery Systems for Immunotherapeutics --Chapter 8. Discovery, Screening Methods, Design Considerations and Scale-up aspects of Immunotherapeutic Drugs -- Chapter 9. Pharmacokinetics, Pharmacodynamics, and Toxicology aspects of Immunotherapeutics -- Chapter 10. Regulatory Affairs and Intellectual Property Rights in Immunotherapeutics -- Chapter 11. Future immunotherapy challenges and perspectives. . Sommario/riassunto This book illustrates the significance and relevance of immunotherapy in modern-day therapeutics. Focusing on the application of immunotherapy in oncology, neurodegenerative and autoimmune diseases, it discusses the drug delivery systems, and pre-clinical and clinical methodologies for immunotherapy-based drugs. It also comprehensively reviews various aspects of immunotherapy, such as regulatory affairs, quality control, safety, and pharmacovigilance.

Further, the book discusses the in vitro validation of therapeutic strategies prior to patient application and management of immunotherapy-related side effects and presents case studies demonstrating the design and development (pre-clinical to clinical) of immunotherapy for various diseases. It also describes various design considerations and the scale-up synthesis of immunotherapeutics and screening methods. Lastly, it explores the important aspect of cost-effectiveness and rational immunotherapy strategies.